Drug Overview Report 2018: Rexulti (brexpiprazole) - Otsuka's Latest Atypical Antipsychotic - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Rexulti" report has been added to ResearchAndMarkets.com's offering.

Rexulti (brexpiprazole) is Otsuka's latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous system.

In November 2011, Otsuka announced that it had signed a long-term agreement with Lundbeck for the development and commercialization of central nervous system products in both companies' pipelines. Rexulti was one of Otsuka's key assets in the deal. In return for $200m upfront, with a potential final deal value of $1.8bn, Lundbeck gained co-development and co-promotion rights to Rexulti and a depot formulation of Abilify. Lundbeck also offered Otsuka the same rights for up to three of its compounds after Phase IIb clinical trials.

Key Topics Covered:

  1. Drug Overview
  2. Product Profiles
  3. Rexulti: Bipolar disorder
  4. Rexulti: Schizophrenia
  5. Rexulti: Depression

For more information about this report visit https://www.researchandmarkets.com/research/qn9vfr/drug_overview?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Disorders Drugs, Schizophrenia Drugs